Figures computed from official regulatory filings — .
Analysttarget 49.67 USD (+73%)
Ownershipinsiders 9.24% · institutions 81.92% · short 17.2% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Liquidia Technologies Inc only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
21 buys13 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| ESHELMAN FREDRIC Ntrack record | Sell | $54.3K | SEC | ||
| Eshelman Ventures, LLCtrack record |
| Sell |
| $892.9K |
| SEC |
| Eshelman Ventures, LLCtrack record | Sell | $421.4K | SEC |
| Eshelman Ventures, LLCtrack record | Other | $100.5K | SEC |
| Eshelman Ventures, LLCtrack record | Buy | $15M | conv 46Unusual size | SEC |
| SNYDERMAN RALPH | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rielly-Gauvin Katherine | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SINGH RAMAN | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RUDNICK SETH | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Horobin Joanna | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kirsch Arthur Strack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bloch Stephen M | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Maynor Benjamin | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Maynor Benjamin | Other | $23.3K | SEC |
| Maynor Benjamin | Exercise | $12.8K | SEC |
| Shah Tushar | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Maynor Benjamin | Other | $20.7K | SEC |
| Maynor Benjamin | Exercise | $11.3K | SEC |
| Maynor Benjamin | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Eshelman Ventures, LLCtrack record | Buy | $233.6K | conv 17 | SEC |
| Eshelman Ventures, LLCtrack record | Buy | $169.8K | conv 18 | SEC |
| Eshelman Ventures, LLCtrack record | Buy | $35.8K | conv 12 | SEC |
| Eshelman Ventures, LLCtrack record | Buy | $220.1K | conv 63First in 12mo | SEC |
| ESHELMAN FREDRIC Ntrack record | Buy | $67.1K | conv 26First in 12mo | SEC |
| ESHELMAN FREDRIC Ntrack record | Buy | $146.1K | conv 33 | SEC |